RASopathy

RASopathies arise when germline variants alter signaling through the RAS–MAPK pathway, which links signals at the cell surface to gene regulation in the nucleus. The pathway includes proteins encoded by genes such as PTPN11, SOS1, RAF1, BRAF, MAP2K1, KRAS, HRAS, and NF1. Depending on the gene and variant, signaling may be increased, reduced, or dysregulated. The resulting developmental effects begin before birth, although some complications become apparent only during childhood or adulthood.

The term includes clinically overlapping conditions rather than one single disease. Major examples are Noonan syndrome, neurofibromatosis type 1, Costello syndrome, cardiofaciocutaneous syndrome, Noonan syndrome with multiple lentigines, and related rarer disorders. Shared facial features or congenital heart disease can suggest the diagnosis, but molecular testing is often needed because the phenotypes overlap.¹

RASopathies are multisystem conditions in which congenital heart disease, characteristic facial development, and variable growth or developmental differences form the central clinical pattern. Pulmonary valve stenosis and hypertrophic cardiomyopathy are especially important cardiac findings, while atrial septal defects and other structural abnormalities also occur. Short stature, delayed puberty, feeding difficulty, webbed or widely spaced nipples, chest-wall differences, and lymphatic abnormalities are frequent in some syndromes.

Skin and hair findings range from café-au-lait macules and neurofibromas in neurofibromatosis type 1 to sparse or curly hair, keratoses, papillomas, and distinctive pigmentation in other disorders. Learning difficulties, speech-language impairment, attention problems, hypotonia, or intellectual disability may occur, but cognitive outcomes are highly variable. Eye abnormalities, hearing loss, seizures, bleeding tendency, and renal or genital anomalies are less universal yet clinically relevant. Cancer risk is elevated in selected RASopathies, particularly neurofibromatosis type 1 and Costello syndrome, rather than uniformly across the group.²

Diagnosis combines clinical examination, family history, targeted investigations, and genetic testing rather than relying on one defining physical feature.¹ A multigene panel or exome-based test may identify a pathogenic variant when the presentation is atypical; a negative result does not exclude a RASopathy because some causative genes or variants remain difficult to detect. Testing also helps distinguish inherited disease from a new variant and supports recurrence-risk assessment through genetic counseling.

Management is coordinated and surveillance-based. Echocardiography and electrocardiography assess cardiac disease; growth, nutrition, endocrine function, vision, hearing, development, and school needs require periodic review. Treatment may include cardiac procedures, nutritional support, hormone therapy in selected cases, educational services, and psychological or speech-language intervention. Tumor surveillance follows the specific syndrome: routine investigations should be guided by established risk rather than applied identically to every RASopathy. MEK inhibitors and other pathway-directed drugs are established treatments for some complications, but their use remains condition- and indication-specific.

The apparent boundaries between RASopathies are biologically blurred: the same gene can produce different syndromes, and different genes can produce a similar phenotype. Variant position, biochemical effect, genetic background, and mosaicism can all influence presentation. Some people with a pathogenic variant have subtle findings and are diagnosed only after a child or relative is evaluated, while others have severe prenatal or neonatal disease.

RASopathy research has also influenced cancer biology because the same signaling proteins that shape development are frequently altered in tumors. This connection has encouraged clinical trials of pathway inhibitors, but developmental disorders cannot simply be treated as cancers: dosage, age, tissue effects, and long-term safety differ. Another overlooked feature is the importance of lymphatic disease, including prenatal fluid accumulation, persistent swelling, or postoperative chylous leakage in selected patients. Adult care remains necessary, since cardiomyopathy, rhythm disorders, fertility concerns, and psychosocial needs may persist after pediatric follow-up ends.³

RAS/MAPK pathway

A chain of intracellular signals that regulates proliferation, differentiation, survival, and development.

Germline variant

A genetic change present in the egg or sperm lineage and therefore potentially present throughout an affected person's body.

Hypertrophic cardiomyopathy

Abnormal thickening of the heart muscle that can impair filling or produce rhythm complications.

Mosaicism

The presence of genetically distinct cell populations within one individual, sometimes producing a milder or patchier phenotype.

MEK inhibitor

A drug that blocks MEK, a signaling protein in the RAS/MAPK pathway; use depends on the disease and clinical indication.